Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 212
- Registration Number
- NCT02336750
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Aprepitant to Mitigate Opioids' Cognitive Side Effects
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 50
- Registration Number
- NCT02226601
- Locations
- 🇺🇸
University of Arizona Medical Center, Tucson, Arizona, United States
Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
- Conditions
- Interventions
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- The Scripps Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02210195
- Locations
- 🇺🇸
The Scripps Research Institute, La Jolla, California, United States
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 244
- Registration Number
- NCT02161991
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 12
- Registration Number
- NCT02154360
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania Clinical Research Site, Philadelphia, Pennsylvania, United States
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 106
- Registration Number
- NCT02130687
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 15
- Registration Number
- NCT02097823
- Locations
- 🇺🇸
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
Topical Aprepitant in Prurigo Patients
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT01963793
- Locations
- 🇩🇪
Allergie-Zentrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany
The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 125
- Registration Number
- NCT01897337
- Locations
- 🇰🇷
Gangnam severance hospital, Seoul, Korea, Republic of
Differentiating the Effects of Substance P and Beta-endorphin
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01854177
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.